Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 881 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period C Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.

NCT00713791
View directory record Official record
Conditions
Healthy
Interventions
ZD4054
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants

NCT01464450
View directory record Official record
Conditions
Pharmacokinetics, Bioavailability, Healthy Participants
Interventions
Rivaroxaban
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 26, 2026, 7:15 PM EDT
Recruiting Phase 2Phase 3 Interventional

Randomized Controlled Trial of Treatment to Optimize Heart Rate Variability for Persistent Post-Concussion Symptoms

NCT07071350
View directory record Official record
Conditions
Autonomic Nervous System Disease, Concussive Injury, Mild Traumatic Brain Injury, Post Traumatic Stress Disorder, Persistent Post Concussion Syndrome
Interventions
HRV Coherence Ratio, NSI, Pittsburgh Sleep Quality Index (PSQI), Quantitative Sleep Measures, Patient Global Impression of Change (PGIC), Cognitive Performance/NIH Toolbox Cognitive Battery, Pain Interference/TBI-QoL Pain Interference Short-Form, Patient Health Questionnaire-9 (PHQ-9), PTSD Checklist for DSM-5 (PCL-5), HRV Biofeedback (HRV-B), Psychoeducational (Edu) Comparator Intervention
Other · Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

NCT01392703
View directory record Official record
Conditions
Pharmacokinetic Study in Healthy Participants
Interventions
Dasatinib as tablets, Dasatinib as liquid, Dasatinib as dispersed tablets
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-2225 in Healthy Participants (MK-2225-003)

NCT06643390
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
MK-2225, Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

New Treatment Option for Pancreatic Cancer

NCT01364805
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Intravenous Vitamin C, Gemcitabine
Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

NCT02853435
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Evaluation of Nalmefene Formulations

NCT07543276
View directory record Official record
Conditions
Opioid Overdose
Interventions
Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection
Drug
Lead sponsor
Knoa Pharma LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

Effect of Fish Oil and Vitamin C on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

NCT01057615
View directory record Official record
Conditions
Asthma
Interventions
Fish Oil, Ascorbic Acid, Fish Oil Placebo, Ascorbic Acid Placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2011 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

NCT03633617
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
62
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

NCT04983264
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT021601
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 26, 2026, 7:15 PM EDT
Withdrawn Phase 4 Interventional

Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers

NCT01766115
View directory record Official record
Conditions
Viral Hepatitis C
Interventions
Telaprevir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

NCT02567682
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

NCT03030105
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 26, 2026, 7:15 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

NCT05438303
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

NCT06143046
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
0 Years to 40 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
22
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

NCT06293742
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

NCT06644924
View directory record Official record
Conditions
Asthma
Interventions
Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
22
States / cities
Encinitas, California • Lancaster, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study of IA-14069

NCT05317741
View directory record Official record
Conditions
Healthy
Interventions
IA-14069, Placebo
Drug
Lead sponsor
ILAb Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 26, 2026, 7:15 PM EDT
Recruiting Not applicable Interventional

Boosting Emotional Well-being and Happiness in Outpatients Living With Diabetes

NCT05420051
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Positive Psychology + Motivational Interviewing, Motivational Interviewing
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 26, 2026, 7:15 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Food Effect Study of Two Formulations of TAK-906

NCT04831502
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 26, 2026, 7:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis

NCT07283770
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-581, Placebo, D-IVA, TEZ, ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 26, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

NCT06945276
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558, Dabigatran, Itraconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 26, 2026, 7:15 PM EDT